Dragonfly Therapeutics (United States)

Recent papers from Dragonfly Therapeutics (United States)

1. Fc-enhanced anti-CCR6 antibody elicits robust therapeutic effects across multiple autoimmune diseasesFrontiers in Immunology · 2026
2. Agonistic anti-NKG2D antibody structure reveals unique stoichiometry and epitope compared to natural ligandsmAbs · 2024
3. Subunit-Selective PI3K Inhibition to Reverse Immunotherapy Resistance: Phase I/II Study of PI3Kβ and Pembrolizumab in Advanced Solid Tumors with PTEN Loss2024
4. A phase 1/1b, first-in-human, multi-part study of DF6215, an engineered IL-2Rα-active agonist, to investigate the safety, tolerability, pharmacokinetics, and biological and clinical activity in patients with advanced solid tumors.Journal of Clinical Oncology · 2024
5. Local and Systemic Management Options for Melanoma Brain MetastasesThe Cancer Journal · 2024
6. Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET® CC-96191Cancers · 2024
7. Direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titerCell Reports Methods · 2022
8. Fibronectin extra domain A as a drug delivery targeting epitope for rheumatoid arthritisRevista Brasileira de Reumatologia · 2022
9. Structures of activin ligand traps using natural sets of type I and type II TGFβ receptorsiScience · 2021
10. Online monitoring and control of upstream cell culture process using 1D and 2D‐LC with SegFlow interfaceBiotechnology and Bioengineering · 2021
11. Expression of meis and hoxa11 in dipnoan and teleost fins provides new insights into the evolution of vertebrate appendagesEvoDevo · 2018